Artivion announces fda pma approval of perclot and transfer of pma to baxter

Artivion to receive $18.75 million milestone payment under previously announced agreement artivion to begin supplying product to baxter under transitional manufacturing and supply agreement atlanta , may 23, 2023 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the u.s. food and drug administration (fda) granted premarket application (pma) approval of perclot absorbable hemostatic system ("perclot") for use to control bleeding in certain open and laparoscopic surgical procedures. artivion sold the perclot product line to baxter international inc. ("baxter"), (nyse: bax), in july 2021.
BAX Ratings Summary
BAX Quant Ranking